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Classification and some properties of triptans 
Triptans are a group of tryptamine-based drugs used in the acute treatment of migraine headaches. Structurally 
related to the neurotransmitter serotonin, triptans acts by selectively binding to serotonin type-1D receptors. The 
present paper submitted the classification and some properties of triptans (almotriptan, eletriptan, frovatriptan, 
naratriptan, sumatriptan, rizatriptan, zolmitriptan). 
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Migraine is a common, chronic, multifactorial neurovascular disorder, typically characterised by 
recurrent disabling attacks of severe headache, autonomic nervous system dysfunction and, in up to a third 
of patients, neurological aura symptoms. The triptans, selective serotonin 5-HT1B/1D agonists, are very 
effective acute migraine drugs with a well developed scientific rationale [9]. Structurally related to the 
neurotransmitter serotonin, triptans acts by selectively binding to serotonin type-1D receptors. The 
mechanism of action of triptans drugs is not exactly known. However, it is thought to involve: the cranial 
blood vessels, the trigeminal innervation of these vessels, the reflex connection of the trigeminovascular 
system in the cranial parasympathetic outflow. 
Sumatriptan was the first of these compounds to be developed. Later, second-generation triptans were 
developed, namely, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, and zolmitriptan. Triptans have 
selective pharmacology, simple and consistent pharmacokinetics, evidence-based prescribing instructions, 
well established efficacy, modest side-effects, and a well established safety record. 
The most serious side effects of triptans are heart attacks and strokes. Triptans can interact with other 
drugs which cause a serotonin syndrome when given together with a selective serotonin reuptake 
inhibitor [17]. The chemical structure of triptans follows. 
Almotriptan, a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist. Almotriptan binds 
with high affinity to 5-HT1D, 5-HT1B and 5-HT1F receptors. Almotriptan malate is chemically designated as 
1-[[[3-[2-(dimethylamino)ethyl]-1H-indol-5-l]methyl]sulfonyl]pyrrolidine (±)-hydroxy butanedioate (1:1), 
having a molecular weight of 469,56. Almotriptan malate is a white to slightly yellow crystalline powder 
which is soluble in water and sparingly soluble in methanol. It is chemically related to sumatriptan, selective 
for cranial, as opposed to peripheral vasculature and shown potent affinity for 5-HT1B/1D receptors in the 
central nervous system. The pharmacodynamic profiles of almotriptan were extensively investigated using 
in vitro and in vivo animal models. The drug is absorbed well orally, with an absolute bioavailability of 
around 70 % [1; 14; 16].  
Eletriptan is a novel, orally active, selective serotonin 5-HT1B/1D receptor agonist. Eletriptan hydrobromide 
is chemically designated as (R)-3-[(1-methyl-2-pyrrolidinyl) methyl]-5-[2-(phenylsulfonyl) ethyl]-1H-indole 
monohydrobromide. Eletriptan hydrobromide used for the treatment of acute migraine headaches. Its phar-
macological effects include the constriction of cerebral blood vessels and neuropeptides secretion blockade 
which eventually relieves the pain. The pharmacokinetics and metabolism of eletriptan hydrobromide have 
been investigated in the rat, dog and human. In all three species, eletriptan hydrobromide was rapidly absor-
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bed and extensively cleared by metabolism. The pathways of eletriptan metabolism are similar in the rat, 
dog and human and principal routes include pyrrolidine N-desmethyl eletriptan, together with N-oxidation, 
oxidation of the pyrrolidine ring and formation of tetra cyclic quaternary ammonium metabolites [4]. 
Sheme 1 
Brutto and structural formulas of triptans 
Sumatriptan / C14H21N3O2S 
 
Almotriptan / C17H25N3O2S 
 
Naratriptan / C17H25N3O2S 
 
Eletriptan / C22H26N2O2S 
 
Rizatriptan / C15H19N5·C7H6O2 
 
Frovatriptan / C14H17N3O 
 
Zolmitriptan /C16H21N3O2 
 
Frovatriptan, administered as a single enantiomer (R)-(+)-3-(methylamino)-1,2,3,4-tetrahydro-9H-car-
bazole-6-carboxamide is a potent 5-HT1B/1D receptor agonist, one with a long duration of action and good 
tolerability. Frovatriptan reverses cerebral vasodilation by activating 5-HT1B, and it prevents neurogenic 
inflammation by activating 5-HT1D. Frovatriptan is not only more potent but also unlike sumatriptan, 
zolmitriptan and naratriptan which fall into the category of triptamine derivatives, does not appear to 
constrict human coronary and peripheral arteries. Molecular weight is 243,304 g/mol [6]. 
Naratriptan is chemically known as N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl] ethane 
sulfonamide, which corresponds to a molecular weight of 335,47 g/mol. It is a triptan drug used for the 
treatment of migraine headaches, and is a selective 5-HT1B/1D receptor subtype agonist. The probable sites of 
therapeutic action of naratriptan include cranial vasculature; the peripheral terminations of trigemino-
vascular sensory nerves; the first order synapses of the trigeminovascular sensory system; the descending 
pain control system; and the nuclei of the thalamus. It is well absorbed (74 % oral bioavailability with peak 
plasma concentrations after 2−5 hours) having 28−31 % protein binding, and is metabolized by a wide range 
of cytochrome P450 isoenzymes into a number of inactive metabolites, and has a 5−8 hour half life [10; 15]. 
Sumatriptan (3-[2-(dimethylamino)ethyl]-n-methyl-1H-indole-5-methane-sulphonamide succinate) is 
a highly selective 5-HT1B/1D receptor agonist. It is a triptan drug which is effectively used in the treatment of 
migraine and cluster headache attacks. Sumatriptan is the first and most widely prescribed triptan. It is 
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administered in several dosage forms including products for nasal, oral and rectal delivery [10]. The drug is 
official in European, British and USP and suggests chromatographic methods for determination of suma-
triptan in bulk and tablet formulations [5; 8; 18]. 
Rizatriptan (N,N-dimethyl-2-[5-(1,2,4-triazole-1-ylmethyl)-1H-indol-3-yl] ethanamine monobenzoate). 
Rizatriptan is also a triptan drug and it is a selective 5-HT1B/1D receptor agonist. Rizatriptan binds with high 
affinity to human cloned 5-HT1B and 5-HT1D кeceptors. Rizatriptan has weak affinity for other 5-HT1 recep-
tor subtypes (5-HT1A, 5-HT1E, and 5-HT1F) and the 5-HT7 receptor, but has no significant activity at 5-HT2, 
5-HT3, α- and -adrenergic, dopaminergic, histaminergic, muscarinic or benzodiazepine receptors. After oral 
doses, peak plasma rizatriptan concentrations are obtained in about 1 to 1,5 hours depending on the formu-
lation. Bioavailability is about 40 % to 45 %. Food may daily to the peak plasma concentrations of the tablet 
formulation by about 1 hr, plasma protein binding is low (14 %). Rizatriptan metabolized primarily by 
MOA type A to the inactive indole acetic acid derivative. The active metabolite N-monodesmethyl rizatrip-
tan is formed to a minor degree, other mono metabolites are also produced. About 14 % of the indole acetic 
acid metabolite and 1% as N-monodesmethyl rizatriptan. The plasma half life is about 2−3 hours [3]. 
Zolmitriptan (4(S)-4-[3-(2-dimethylaminoethyl)-1H-5-indolylmethyl]-1,3-oxazolan-2-one) is a second-
generation triptan prescribed for patients with migraine attacks, with and without an aura, and cluster 
headaches. It has a selective action on serotonin receptors and is very effective in reducing migraine symp-
toms, including pain, nausea and photo- or phonophobia. In liver, zolmitriptan is well absorbed and under-
goes extensive metabolism. Its major metabolites are 4(S)-4-[3-(2-methylaminoethyl)-1H-5-indolyl-methyl]-
1,3-oxazolan-2-one and (4S)-4-[3-[2-(dimethyloxidoamino)ethyl]-1H-indol-5-yl]methyl-2-oxazolidinon. It 
is currently available as a conventional tablet, an oral disintegrating tablet and a nasal spray. The absolute 
bioavailability of zolmitriptan is up to 40% for both oral and nasal dosage forms [2; 12; 13]. 
The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs with a well 
developed scientific rationale. Seven different triptans will soon be clinically available, making evidence-
based selection guidelines necessary. Triptan trials have similar designs, facilitating meta-analysis; this will 
provide a foundation for using triptans in clinical practice [7]. 
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Антал Ірина. Класифікація та деякі властивості триптанів. Триптани – нова група ефективних проти-
мігренних препаратів. Вони є специфічними селективними агоністами 5НТ1D-серотонінових рецепторів. У 
статті наведено класифікацію та деякі властивості триптанів (алмотриптану, золмітриптану, наратриптану, 
суматриптану, ризатриптану, фроватриптану й елетриптану). 
Ключові слова: триптани, класифікація, властивості. 
Антал Ирина. Классификация и некоторые свойства триптанов. Триптаны – новая группа эффектив-
ных противомигренозных препаратов. Они являются специфическими селективными агонистами 5НТ1D-серо-
тониновых рецепторов. Статья содержит сведенья о классификации и некоторых свойствах триптанов (алмо-
триптана, золмитриптана, наратриптана, суматриптана, ризатриптана, фроватриптана и элетриптана). 
Ключевые слова: триптаны, классификация, свойства. 
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